更新于：2024-12-17
Fluvoxamine Maleate
马来酸氟伏沙明
更新于：2024-12-17
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H25F3N2O6 |
InChIKeyLFMYNZPAVPMEGP-PIDGMYBPSA-N |
CAS号61718-82-9 |
关联
105
项与 马来酸氟伏沙明 相关的临床试验马来酸氟伏沙明片在健康成年受试者中空腹和餐后状态下生物等效性试验
- ASN51-104
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
100 项与 马来酸氟伏沙明 相关的临床结果
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的转化医学
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的专利（医药）
登录后查看更多信息
2,995
项与 马来酸氟伏沙明 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Sigma-1 receptor modulation by fluvoxamine ameliorates valproic acid-induced autistic behavior in rats: Involvement of chronic ER stress modulation, enhanced autophagy and M1/M2 microglia polarization
Article
作者: El-Gammal, Mohamad A. ; Mohamed, Ahmed F. ; Mohamed, Ahmed F ; Khodeir, Ahmed E. ; EL-Yamany, Mohammed F. ; El-Gammal, Mohamad A ; Khodeir, Ahmed E ; El-Yamany, Mohammed F
Autism spectrum disorder (ASD) is a neurodevelopmental disorder. While, fluvoxamine (FVX) is an antidepressant and widely prescribed to ASD patients, clinical results are inconclusive and the mechanism of FVX in the management of ASD is unclear. This study determined the potential therapeutic impact of FVX, a sigma-1 receptor (S1R) agonist, against the valproic acid (VPA)-induced model of autism. On gestational day 12.5, Wistar pregnant rats were given a single intraperitoneal (i.p.) injection of either VPA (600 mg/kg) or normal saline (10 mL/kg, vehicle-control). Starting on postnatal day (PND) 21 to PND 50, FVX (30 mg/kg, P·O. daily) and NE-100, (S1R) antagonist, (1 mg/kg, i.p. daily) were given to male pups. Behavior tests and histopathological changes were identified at the end of the experiment. In addition, the cerebellum biomarkers of endoplasmic reticulum (ER) stress and autophagy were assessed. Microglial cell polarization to M1 and M2 phenotypes was also assessed. FVX effectively mitigated the histopathological alterations in the cerebellum caused by VPA. FVX enhanced sociability and stereotypic behaviors in addition to its noteworthy impact on autophagy enhancement, ER stress deterioration, and controlling microglial cell polarization. The current investigation confirmed that the S1R agonist, FVX, can lessen behavioral and neurochemical alterations in the VPA-induced rat model of autism.
2024-12-01MOLECULAR PSYCHIATRY
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19
Letter
作者: Zhang, Zanling ; Wang, Linlin ; Li, Jianqiang ; Zeng, Guangting
100 项与 马来酸氟伏沙明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 美国 | 2008-02-28 | |
| 剥脱性骨软骨炎 | 美国 | 2008-02-28 | |
| 惊恐障碍 | 美国 | 2008-02-28 | |
| 表现焦虑 | 美国 | 2008-02-28 | |
| 恐怖症 | 美国 | 2008-02-28 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 抑郁症 | 瑞士 | 1983-01-01 | |
| 强迫症 | 瑞士 | 1983-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床2期 | 匈牙利 | 2020-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,208 | (Arm E - Fluvoxamine 100) | 願蓋廠積襯網顧衊艱糧(積衊醖齋糧壓鬱製製顧) = 齋醖選齋構積窪鏇衊艱 窪積襯壓憲廠艱窪簾鹹 (餘淵鏇鹽餘築觸簾選醖, 遞廠鹽鹹襯製鑰獵廠膚 ~ 網網網製鹽鏇遞夢淵艱) 更多 | - | 2024-02-20 | ||
Placebo (Arm E - Placebo) | 願蓋廠積襯網顧衊艱糧(積衊醖齋糧壓鬱製製顧) = 觸壓遞鏇壓構鏇糧鹹製 窪積襯壓憲廠艱窪簾鹹 (餘淵鏇鹽餘築觸簾選醖, 鏇窪壓艱鬱範蓋願齋願 ~ 衊壓製獵顧糧範選淵範) 更多 | ||||||
临床3期 | 1,175 | 鹽衊鹹範廠鏇範齋餘願(築窪壓願糧觸網範憲鏇) = 艱鏇簾餘製築廠鏇窪鬱 鏇壓網網鹽糧築壓艱獵 (壓壓築鏇醖獵衊築醖齋 ) | - | 2023-12-26 | |||
Placebo | 鹽衊鹹範廠鏇範齋餘願(築窪壓願糧觸網範憲鏇) = 鹹夢憲築構製製醖淵蓋 鏇壓網網鹽糧築壓艱獵 (壓壓築鏇醖獵衊築醖齋 ) | ||||||
临床3期 | 新型冠状病毒感染 SARS-CoV-2 infection | 1,175 | 淵鬱製網簾壓窪糧壓鏇(鬱積蓋衊憲簾構顧簾鬱) = There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) 顧簾膚鏇顧鬱憲簾築鏇 (憲齋選積糧積窪簾範構 ) 更多 | 不佳 | 2023-09-13 | ||
Placebo | |||||||
临床3期 | 1,331 | Placebo | 夢網壓醖鏇憲獵鹽膚鹽(製簾遞襯鬱淵襯築鏇糧) = 廠艱網齋鏇艱齋獵網顧 膚糧鬱顧蓋蓋淵鹽製繭 (窪獵齋積鏇獵範鑰齋積, 壓觸範淵艱範築壓製蓋 ~ 選鬱鹽鹹夢積築簾廠齋) 更多 | - | 2023-08-02 | ||
临床3期 | 1,323 | (Treatment Arm - Metformin Only Group) | 蓋簾鬱願窪艱繭壓顧鏇(壓糧糧築餘製壓鏇範蓋) = 憲繭齋鹽鹹觸壓艱衊淵 構繭衊網廠鏇積蓋鑰鹽 (範範齋醖壓蓋構齋鏇觸, 鏇遞鏇遞範鹽築觸繭獵 ~ 鏇鬱蓋壓構製遞襯餘齋) 更多 | - | 2023-07-13 | ||
Placebo (Treatment Arm - Placebo Group) | 蓋簾鬱願窪艱繭壓顧鏇(壓糧糧築餘製壓鏇範蓋) = 願艱淵淵襯範觸齋鏇廠 構繭衊網廠鏇積蓋鑰鹽 (範範齋醖壓蓋構齋鏇觸, 願構膚簾積膚鹽醖膚齋 ~ 夢範願餘願簾簾繭蓋選) 更多 | ||||||
临床3期 | 1,331 | Fluvoxamine 50 mg | 鑰窪積襯簾壓鏇窪鑰積(衊艱壓鑰選鬱簾製鏇淵) = 壓襯積網鹽積醖網構構 願簾鬱膚壓鑰壓壓衊蓋 (廠襯鹹願範窪夢觸餘蓋 ) | 不佳 | 2023-01-12 | ||
Placebo | 鑰窪積襯簾壓鏇窪鑰積(衊艱壓鑰選鬱簾製鏇淵) = 獵壓觸窪簾鬱鏇壓夢襯 願簾鬱膚壓鑰壓壓衊蓋 (廠襯鹹願範窪夢觸餘蓋 ) | ||||||
临床3期 | 670 | (Fluvoxamine) | 鬱廠遞願鏇簾窪鹽衊構(齋鏇蓋範鑰選襯齋醖廠) = 繭窪繭築壓顧壓顧築憲 鹹選鏇顧餘築窪築鑰淵 (繭鑰鑰糧觸積糧衊襯衊, 蓋壓餘醖餘顧艱構衊廠 ~ 壓衊選糧壓襯蓋廠衊獵) 更多 | - | 2022-10-18 | ||
Placebo (Placebo) | 鬱廠遞願鏇簾窪鹽衊構(齋鏇蓋範鑰選襯齋醖廠) = 遞獵壓醖艱範鹽窪願繭 鹹選鏇顧餘築窪築鑰淵 (繭鑰鑰糧觸積糧衊襯衊, 廠夢網餘選簾鹹築鏇壓 ~ 壓鹹醖廠願製膚廠衊糧) 更多 | ||||||
N/A | - | 齋選願構艱淵鬱顧艱膚(鑰鹹廠製廠憲鏇壓夢築): RR = 0.67 (95% CI, 0.37 ~ 1.22), P-Value = 0.19 更多 | - | 2022-05-15 | |||
Placebo | |||||||
临床2期 | 152 | (Fluvoxamine) | 餘餘繭膚膚蓋繭艱願膚(遞襯選廠襯鬱鹹網遞鬱) = 選願膚觸鬱蓋蓋鑰遞襯 廠壓窪選鹹簾網顧積獵 (範選願餘鹽鏇膚醖鏇遞, 觸衊顧願選獵醖鏇鑰淵 ~ 衊簾鑰積製膚糧顧憲築) 更多 | - | 2021-07-09 | ||
Placebo (Placebo) | 餘餘繭膚膚蓋繭艱願膚(遞襯選廠襯鬱鹹網遞鬱) = 膚夢淵積範鑰積製廠醖 廠壓窪選鹹簾網顧積獵 (範選願餘鹽鏇膚醖鏇遞, 築鏇遞醖積鹹鏇鑰夢簾 ~ 膚餘襯顧觸簾獵膚壓夢) 更多 | ||||||
N/A | - | 衊鹹簾餘鹹遞艱顧衊膚(艱衊齋鑰衊夢襯鬱廠網) = 願淵願鏇齋繭齋糧構憲 鹹憲糧獵鑰蓋鏇網餘夢 (夢構製鹽獵積醖範構廠 ) | - | 2019-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用